Shouyao Holdings Beijing Co. Ltd. Class A
SSSE:68819733.12
CNY
-0.32
(-0.96%)
ISIN
CNE1000062V6
Return %
Stock
S&P 500
1Y
-17.22
14.20
3Y
-19.28
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Wen Jun Li
- Full Time Employees
- 172
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Beijing China
- IPO Date
- Aug 24, 2023
- Website
- shouyaoholding.com
- Similar Companies
- Business
- Shouyao Holdings (Beijing) Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule targeted therapies for the treatment of oncology and other life-threatening diseases. The company engages in the research, design, and clinical progression of proprietary chemical drugs designed to inhibit specific oncogenic pathways across solid tumors and hematologic malignancies. Its product pipeline comprises several clinical-stage candidate therapies, including SY-707, a multi-targeted kinase inhibitor directed against ALK, FAK, and IGF-1R for advanced or metastatic ALK-positive non-small cell lung cancer; SY-3505, a third-generation ALK tyrosine kinase inhibitor engineered to address resistance mutations emerging from first- and second-generation ALK inhibitors; SY-5007, a potent and selective RET kinase inhibitor for the treatment of RET fusion-positive non-small cell lung cancer and RET-mutant thyroid carcinomas; SY-1530, an irreversible small-molecule BTK inhibitor developed for B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia; SY-4835, a selective WEE1 kinase inhibitor under clinical evaluation for advanced solid tumors; and various earlier-stage targeted assets encompassing kinase inhibitors, cell cycle regulators, and epigenetic modulators. Alongside internal drug discovery, the company utilizes co-development and licensing arrangements, maintaining strategic partnerships with major domestic pharmaceutical companies, including Chia Tai Tianqing Pharmaceutical Group and CSPC Pharmaceutical Group, to advance selected clinical programs under milestone and royalty-sharing frameworks. In recent operational and clinical developments, Shouyao Holdings achieved key regulatory progression with the National Medical Products Administration accepting the New Drug Application for its lead oncology asset SY-707 for ALK-positive non-small cell lung cancer, initiated pre-NDA communications and advanced registrational clinical trials for its selective RET inhibitor SY-5007, presented pivotal Phase II clinical trial data for its third-generation ALK inhibitor SY-3505 at international oncology conferences, and continued to scale its clinical development pipeline toward domestic commercialization readiness. Founded in 2016, Shouyao Holdings (Beijing) Co., Ltd. is headquartered in Beijing, China, and lists its Class A ordinary shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange.